FDA Releases MannKind from Major Afrezza Postmarketing Trial; Pediatric PDUFA Tomorrow
MNKD sits 59% above its 52-week low of $2.23.
Summary
MannKind announced a significant regulatory win as the FDA released it from a major postmarketing trial for Afrezza, while also highlighting an imminent PDUFA date for pediatric Afrezza.
Key Events · Product Development and Regulatory · MNKD
-
FDA Releases from Major Postmarketing Requirement
The U.S. Food and Drug Administration (FDA) released MannKind from a five-year, 8,000-10,000 patient postmarketing trial for Afrezza, which was required to assess the risk of pulmonary malignancy in type 2 diabetes patients.
-
Imminent PDUFA Date for Pediatric Afrezza
The PDUFA target action date for the supplemental Biologics License Application (sBLA) for Afrezza in children and adolescents (ages 4-17) with type 1 or type 2 diabetes is May 29, 2026, which is tomorrow.
-
INHALE-1st Clinical Study Expansion
Eight additional sites have been activated for the INHALE-1st study, which evaluates Afrezza plus basal insulin for youth aged 10-17 with newly-diagnosed type 1 diabetes. Data from this study is expected in late 2027.
Analysis · MNKD · Life Sciences
The FDA's decision to release MannKind from a large, five-year postmarketing trial for Afrezza significantly reduces future regulatory burden, costs, and potential risks associated with the drug. This de-risking event improves Afrezza's long-term commercial outlook. Additionally, the imminent PDUFA target action date for pediatric Afrezza presents a near-term opportunity for market expansion, which could further boost sales.
At the time of this filing, MNKD was trading at $3.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.